<DOC>
	<DOC>NCT01680159</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment with Remicade® at 5 mg/kg every 8 weeks but decreased thereafter.</brief_summary>
	<brief_title>A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis</brief_title>
	<detailed_description>- Patients with plaque psoriasis or psoriatic arthritis: 1. Screening Period: TA-650 at 5 mg per kg body weight is administered on the day of TA-650 administration at the start (week 0) and week 8 (if efficacy is not judged as decreased or maintained at week 8 of the screening period) , respectively, by intravenous infusion slowly over at least 2 hours. 2. Increased Dose Period: If efficacy is judged as decreased in the screening period, TA-650 at 10 mg per kg body weight is administered on the day of TA-650 administration at the start (week 0) and at every 8 weeks up to week 32 in the increased dose period , respectively, as one dose by intravenous infusion slowly over at least 2 hours. - Patients with pustular psoriasis or psoriatic erythroderma: TA-650 at 10 mg per kg body weight is administered on the day of TA-650 administration at the start (week 0) and at every 8 weeks up to week 32, respectively, as one dose by intravenous infusion slowly over at least 2 hours.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Dermatitis, Exfoliative</mesh_term>
	<criteria>Patients who have already been diagnosed as having plaque psoriasis, psoriatic arthritis, pustular psoriasis (excluding a localized), or psoriatic erythroderma. Patients in whom effect of the treatment was confirmed for a certain period after the start of administration of Remicade® at 5 mg/kg at every 8 weeks but decreased thereafter. Patients who have guttate psoriasis. Patients who have druginduced psoriasis Patients who have previously used any other biological products than infliximab. Patients who have a concomitant diagnosis, or a history within 6 months prior to provisional enrollment, of serious infections that need hospitalization. Patients who have a concomitant diagnosis, or a history within 6 months prior to provisional enrollment, of opportunistic infections Female patients who are pregnant, breastfeeding, or possibly pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>REMICADE</keyword>
	<keyword>TA-650</keyword>
	<keyword>psoriasis</keyword>
</DOC>